Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Bladder cancer in 2016

News in diagnosis, treatment, and risk group assessment

Nature Reviews Urology volume 14, pages 74–76 (2017)Cite this article

Subjects

2016 has been a good year for research in non-muscle-invasive bladder cancer. Topics to see progress include risk assessment of patients treated with BCG maintenance, the role of repeat transurethral resection of the bladder (TURB), a prospective study of white-light versus narrow-band imaging, a meta-analysis regarding single instillation chemotherapy, and the effect of the use of fluorescence-guided TURB on progression.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cambier, S. et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus Calmette–Guérin. Eur. Urol. 69, 60–69 (2016).

    Article  PubMed  Google Scholar 

  2. Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466–475 (2006).

    Article  PubMed  Google Scholar 

  3. Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666–675 (2001).

    Article  CAS  PubMed  Google Scholar 

  4. Gontero, P. et al. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette–Guérin.BJU Int. 118, 44–52 (2016).

    Google Scholar 

  5. Babjuk, M. et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2016.05.041 (2016).

  6. Divrik, R. T. et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J. Urol. 175, 1641–1644 (2006).

    Article  CAS  PubMed  Google Scholar 

  7. Vasdev, N. et al. The impact of early re-resection in patients with pT1 high-grade non-muscle invasive bladder cancer. Ecancermedicalscience 6, 269 (2012).

    PubMed  PubMed Central  Google Scholar 

  8. Naito, S. et al. The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. Eur. Urol. 70, 506–515 (2016).

    Article  PubMed  Google Scholar 

  9. Sylvester, R. J. et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa–pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur. Urol. 69, 231–244 (2016).

    Article  PubMed  Google Scholar 

  10. Gakis, G. & Fahmy, O. Systematic review and meta-analysis on the impact of hexaminolevulinate- versus white-light guided transurethral bladder tumor resection on progression in non-muscle invasive bladder cancer. Bladder Cancer 2, 293–300 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Richard Zigeuner is at the Department of Urology, Medical University of Graz, Auenbruggerplatz 5/6, A-8036 Graz, Austria.,

    Richard Zigeuner

Authors
  1. Richard Zigeuner
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Richard Zigeuner.

Ethics declarations

Competing interests

The author declares that he has received speaker's honoraria and travel support from Amgen, Astellas, Bayer, GlaxoSmithKline, Ipsen, Novartis, Pfizer, Roche, and Takeda.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zigeuner, R. News in diagnosis, treatment, and risk group assessment. Nat Rev Urol 14, 74–76 (2017). https://doi.org/10.1038/nrurol.2016.264

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2016.264

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing